- ICH GCP
- Yhdysvaltain kliinisten tutkimusten rekisteri
- Kliininen tutkimus NCT04982588
Evolut PRO Kiinan kliininen tutkimus
Medtronic CoreValve™ Evolut™ PRO -järjestelmän Kiinan kliininen tutkimus
Interventional study to evaluate the safety and efficacy of the Medtronic CoreValve™ Evolut™ PRO System when used by China implanting centers in Chinese patients with severe symptomatic aortic stenosis (AS) who are at high risk for Surgical Aortic Valve Replacement (SAVR).
Tutkimuksen yleiskatsaus
Tila
Interventio / Hoito
Yksityiskohtainen kuvaus
The study is targeting 6 centers with a maximum of 8 centers in China and estimating 65 subjects with a maximum of up to 70 subjects with attempted implants including 50 subjects with an attempted implant in primary study population and the first two attempted subjects at each site for roll-in population. The subjects will follow the assessment with pre and post-procedure, discharge, 30 days(primary endpoint), 6 months, 1 year, and annually through 5 years.
Opintotyyppi
Ilmoittautuminen (Todellinen)
Vaihe
- Ei sovellettavissa
Yhteystiedot ja paikat
Opiskelupaikat
-
-
Beijing Municipality
-
Beijing, Beijing Municipality, Kiina, 100000
- Chinese PLA General Hospital, Chinese PLA Medical School
-
Beijing, Beijing Municipality, Kiina, 100000
- Beijing Anzhen Hospital, Capital Medical University
-
-
Sichuan
-
Chengdu, Sichuan, Kiina, 610000
- West China Hospital of Sichuan University
-
-
Zhejiang
-
Hangzhou, Zhejiang, Kiina, 310009
- The Second Affiliated Hospital Zhejiang University School of Medicine
-
-
Osallistumiskriteerit
Kelpoisuusvaatimukset
Opintokelpoiset iät
Hyväksyy terveitä vapaaehtoisia
Sukupuolet, jotka voivat opiskella
Kuvaus
Inclusion Criteria:
- Aortic valve area (AVA) < 1.0 cm2 (or indexed AVA <0.6 cm2/m2) OR mean gradient > 40 mmHg, OR max aortic velocity > 4.0 m/sec
- High risk for SAVR defined as STS-PROM score ≥ 8% AND ≤ 15%, OR documented Heart Team agreement of high risk for AVR due to frailty or comorbidities
- Symptoms of aortic stenosis and NYHA ≥ II
Exclusion Criteria:
- Age is less than 65 years old
- Non-calcified aortic valve
- Bicuspid aortic valve with no raphe or 2 raphes (Sievers classification type 0 or type 2)
- Ascending aortic diameter > 4.5 cm
Opintosuunnitelma
Miten tutkimus on suunniteltu?
Suunnittelun yksityiskohdat
- Ensisijainen käyttötarkoitus: Hoito
- Jako: Ei käytössä
- Inventiomalli: Yksittäinen ryhmätehtävä
- Naamiointi: Ei mitään (avoin tarra)
Aseet ja interventiot
Osallistujaryhmä / Arm |
Interventio / Hoito |
|---|---|
|
Kokeellinen: Medtronic CoreValve™ Evolut™ PRO System
The system comprised of the following three components:
|
The system comprised of the following three components:
|
Mitä tutkimuksessa mitataan?
Ensisijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
All-cause Mortality
Aikaikkuna: 30 days
|
All-cause mortality at 30 days |
30 days
|
|
Percentage (%) of Subjects With Evaluable Echocardiograms With Moderate or Severe Aortic Regurgitation by Transthoracic Echocardiography (TTE)
Aikaikkuna: 30 days
|
Percentage (%) of Subjects with evaluable echocardiograms with moderate or severe aortic regurgitation by transthoracic echocardiography (TTE) |
30 days
|
Toissijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Incidence of an VARC II Combined Composite
Aikaikkuna: 30 days
|
Incidence of an VARC II combined composite includes the following components:
|
30 days
|
|
Event Rates of the Individual Components of the VARC II Composite
Aikaikkuna: 30 days
|
Event rate of the individual components listed in the outcome |
30 days
|
|
New Permanent Pacemaker Rate
Aikaikkuna: 30 days
|
New permanent pacemaker rate |
30 days
|
|
Device Success Rate
Aikaikkuna: Between 24 hours and 7 days post procedure
|
Device success rate:
|
Between 24 hours and 7 days post procedure
|
|
Valve Performance Parameter - Mean Aortic Gradient
Aikaikkuna: 30 days
|
Mean aortic gradient |
30 days
|
|
Valve Performance Parameter - Effective Orifice Area
Aikaikkuna: 30 days
|
Effective orifice area |
30 days
|
|
Valve Performance Parameter -Degree of Aortic Regurgitation (Transvalvular, Paravalvular, Total)
Aikaikkuna: 30 days
|
Degree of aortic regurgitation (transvalvular, paravalvular, total) |
30 days
|
Muut tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Event Rates of TAVI-related Complications
Aikaikkuna: 30 days
|
Rate of the following TAVI-related complications:
|
30 days
|
|
All-cause Mortality
Aikaikkuna: 6 months
|
Percentage of participants with all-cause mortality |
6 months
|
|
All-cause Mortality
Aikaikkuna: 1 year
|
Percentage of participants with all-cause mortality |
1 year
|
|
All Stroke
Aikaikkuna: 6 months
|
Incidence of stroke (disabling and non-disabling) |
6 months
|
|
All Stroke
Aikaikkuna: 1 year
|
Incidence of stroke (disabling and non-disabling) |
1 year
|
|
Myocardial Infarction
Aikaikkuna: 30 days
|
Incidence of MI |
30 days
|
|
Myocardial Infarction
Aikaikkuna: 6 months
|
Incidence of MI |
6 months
|
|
Myocardial Infarction
Aikaikkuna: 1 Year
|
Incidence of MI |
1 Year
|
|
Incidence of Life-threatening Bleeding
Aikaikkuna: 30 days
|
Incidence of life-threatening bleeding:
|
30 days
|
|
Incidence of Life-threatening Bleeding
Aikaikkuna: 6 months
|
Incidence of life-threatening bleeding:
|
6 months
|
|
Incidence of Life-threatening Bleeding
Aikaikkuna: 1 Year
|
Incidence of life-threatening bleeding:
|
1 Year
|
|
New AV-Conduction Disturbances (Left Bundle Branch Block (LBBB) and Right Bundle Branch Block (RBBB))
Aikaikkuna: 30 days
|
Incidence of either LBBB or RBBB |
30 days
|
|
Incidence of Prosthetic Valve Endocarditis
Aikaikkuna: 30 days
|
Incidence of prosthetic valve endocarditis: Any one of the following:
|
30 days
|
|
Incidence of Prosthetic Valve Endocarditis
Aikaikkuna: 6 months
|
Incidence of prosthetic valve endocarditis: Any one of the following:
|
6 months
|
|
Incidence of Prosthetic Valve Endocarditis
Aikaikkuna: 1 Year
|
Incidence of prosthetic valve endocarditis: Any one of the following:
|
1 Year
|
|
Incidence of Prosthetic Valve Thrombosis
Aikaikkuna: 30 days
|
Incidence of Prosthetic valve thrombosis: Any thrombus attached to or near an implanted valve that occludes part of the blood flow path, interferes with valve function, or is sufficiently large to warrant treatment. *Valve-associated thrombus identified at autopsy in a patient whose cause of death was not valve related should not be reported as valve thrombosis. |
30 days
|
|
Incidence of Prosthetic Valve Thrombosis
Aikaikkuna: 6 months
|
Incidence of Prosthetic valve thrombosis: Any thrombus attached to or near an implanted valve that occludes part of the blood flow path, interferes with valve function, or is sufficiently large to warrant treatment. *Valve-associated thrombus identified at autopsy in a patient whose cause of death was not valve related should not be reported as valve thrombosis. |
6 months
|
|
Incidence of Prosthetic Valve Thrombosis
Aikaikkuna: 1 Year
|
Incidence of Prosthetic valve thrombosis: Any thrombus attached to or near an implanted valve that occludes part of the blood flow path, interferes with valve function, or is sufficiently large to warrant treatment. *Valve-associated thrombus identified at autopsy in a patient whose cause of death was not valve related should not be reported as valve thrombosis. |
1 Year
|
|
Valve-related Dysfunction
Aikaikkuna: 1 Year
|
Incidence of valve-related dysfunction defined as moderate or severe prosthetic valve stenosis, or moderate or severe prosthetic regurgitation (per VARC II) |
1 Year
|
|
Incidence of Valve-related Dysfunction Requiring Repeat Procedure
Aikaikkuna: 30 days
|
Incidence of Valve-related dysfunction requiring repeat procedure |
30 days
|
|
Incidence of Valve-related Dysfunction Requiring Repeat Procedure
Aikaikkuna: 6 months
|
Incidence of Valve-related dysfunction requiring repeat procedure |
6 months
|
|
Incidence of Valve-related Dysfunction Requiring Repeat Procedure
Aikaikkuna: 1 Year
|
Incidence of Valve-related dysfunction requiring repeat procedure |
1 Year
|
|
Valve Hemodynamic Performance Metric - Mean Aortic Gradient
Aikaikkuna: 1 year
|
Mean aortic gradient |
1 year
|
|
Valve Hemodynamic Performance Metric - Effective Orifice Area
Aikaikkuna: 1 year
|
Effective orifice area |
1 year
|
|
Valve Hemodynamic Performance Metric - Degree of Aortic Regurgitation (Transvalvular, Paravalvular, Total)
Aikaikkuna: 1 year
|
Degree of aortic regurgitation (transvalvular, paravalvular, total) |
1 year
|
|
New York Heart Association (NYHA) Functional Classification
Aikaikkuna: 30 days
|
New York Heart Association (NYHA) functional classification system is a tool that classifies patients with heart failure into one of four classes according to their degree of systems at rest and with activity. Below are the four classes and the associated patient symptoms (i.e., Class I has no limitations of physical activity vs. Class IV is most symptomatic and patient has symptoms of heart failure at rest). Class I: No limitation of physical activity. Ordinary physical activity does not cause undue fatigue, palpitation or shortness of breath. Class II: Slight limitation of physical activity. Comfortable at rest. Ordinary physical activity results in fatigue, palpitation, shortness of breath or chest pain. Class III: Marked limitation of physical activity. Comfortable at rest. Less than ordinary activity causes fatigue, palpitation, shortness of breath or chest pain. Class IV: Symptoms of heart failure at rest. Any physical activity causes further discomfort. |
30 days
|
|
New York Heart Association (NYHA) Functional Classification
Aikaikkuna: 6 month
|
New York Heart Association (NYHA) functional classification system is a tool that classifies patients with heart failure into one of four classes according to their degree of systems at rest and with activity. Below are the four classes and the associated patient symptoms (i.e., Class I has no limitations of physical activity vs. Class IV is most symptomatic and patient has symptoms of heart failure at rest). Class I: No limitation of physical activity. Ordinary physical activity does not cause undue fatigue, palpitation or shortness of breath. Class II: Slight limitation of physical activity. Comfortable at rest. Ordinary physical activity results in fatigue, palpitation, shortness of breath or chest pain. Class III: Marked limitation of physical activity. Comfortable at rest. Less than ordinary activity causes fatigue, palpitation, shortness of breath or chest pain. Class IV: Symptoms of heart failure at rest. Any physical activity causes further discomfort. |
6 month
|
|
New York Heart Association (NYHA) Functional Classification
Aikaikkuna: 1 Year
|
New York Heart Association (NYHA) functional classification system is a tool that classifies patients with heart failure into one of four classes according to their degree of systems at rest and with activity. Below are the four classes and the associated patient symptoms (i.e., Class I has no limitations of physical activity vs. Class IV is most symptomatic and patient has symptoms of heart failure at rest). Class I: No limitation of physical activity. Ordinary physical activity does not cause undue fatigue, palpitation or shortness of breath. Class II: Slight limitation of physical activity. Comfortable at rest. Ordinary physical activity results in fatigue, palpitation, shortness of breath or chest pain. Class III: Marked limitation of physical activity. Comfortable at rest. Less than ordinary activity causes fatigue, palpitation, shortness of breath or chest pain. Class IV: Symptoms of heart failure at rest. Any physical activity causes further discomfort. |
1 Year
|
|
EQ-5D Quality of Life
Aikaikkuna: 30 days
|
EuroQol Group developed this Quality of Life (QOL) questionnaire referred to as EQ-5D that includes a descriptive system comprising five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems. The patient is asked to indicate his/her health state by ticking the box next to the most appropriate statement in each of the five dimensions. The answers given to ED-5D can be converted into EQ-5D index and utility scores anchored at 0 for death and 1 for perfect health. The EQ-5D Index Score is calculated for each study participant and the descriptive statistical summary of the EQ-5D score for the study population is provided. The EQ-5D Visual Analog Scale (VAS) Score is a scale numbered 0 to 100 (0 is the worse health the patient can imagine and 100 is the best health the patient can imagine). |
30 days
|
|
EQ-5D Quality of Life
Aikaikkuna: 1 Year
|
EuroQol Group developed this Quality of Life (QOL) questionnaire referred to as EQ-5D that includes a descriptive system comprising five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems. The patient is asked to indicate his/her health state by ticking the box next to the most appropriate statement in each of the five dimensions. The answers given to ED-5D can be converted into EQ-5D index and utility scores anchored at 0 for death and 1 for perfect health. The EQ-5D Index Score is calculated for each study participant and the descriptive statistical summary of the EQ-5D score for the study population is provided. The EQ-5D Visual Analog Scale (VAS) Score is a scale numbered 0 to 100 (0 is the worse health the patient can imagine and 100 is the best health the patient can imagine). |
1 Year
|
|
All-cause Mortality
Aikaikkuna: 2 year
|
Percentage of participants with all-cause mortality |
2 year
|
|
All Stroke
Aikaikkuna: 2 year
|
Incidence of stroke (disabling and non-disabling) |
2 year
|
|
Myocardial Infarction
Aikaikkuna: 2 Year
|
Incidence of MI |
2 Year
|
|
Incidence of Life-threatening Bleeding
Aikaikkuna: 2 Year
|
Incidence of life-threatening bleeding:
|
2 Year
|
|
Incidence of Prosthetic Valve Endocarditis
Aikaikkuna: 2 Year
|
Incidence of prosthetic valve endocarditis: Any one of the following:
|
2 Year
|
|
Incidence of Prosthetic Valve Thrombosis
Aikaikkuna: 2 Year
|
Incidence of Prosthetic valve thrombosis: Any thrombus attached to or near an implanted valve that occludes part of the blood flow path, interferes with valve function, or is sufficiently large to warrant treatment. *Valve-associated thrombus identified at autopsy in a patient whose cause of death was not valve related should not be reported as valve thrombosis. |
2 Year
|
|
Valve-related Dysfunction
Aikaikkuna: 2 Year
|
Incidence of valve-related dysfunction defined as moderate or severe prosthetic valve stenosis, or moderate or severe prosthetic regurgitation (per VARC II) |
2 Year
|
|
Incidence of Valve-related Dysfunction Requiring Repeat Procedure
Aikaikkuna: 2 Year
|
Incidence of Valve-related dysfunction requiring repeat procedure |
2 Year
|
|
Valve Hemodynamic Performance Metric - Mean Aortic Gradient
Aikaikkuna: 2 year
|
Mean aortic gradient |
2 year
|
|
Valve Hemodynamic Performance Metric - Effective Orifice Area
Aikaikkuna: 2 year
|
Effective orifice area |
2 year
|
|
Valve Hemodynamic Performance Metric - Degree of Aortic Regurgitation (Transvalvular, Paravalvular, Total)
Aikaikkuna: 2 year
|
Degree of aortic regurgitation (transvalvular, paravalvular, total) |
2 year
|
|
New York Heart Association (NYHA) Functional Classification
Aikaikkuna: 2 Year
|
New York Heart Association (NYHA) functional classification system is a tool that classifies patients with heart failure into one of four classes according to their degree of systems at rest and with activity. Below are the four classes and the associated patient symptoms (i.e., Class I has no limitations of physical activity vs. Class IV is most symptomatic and patient has symptoms of heart failure at rest). Class I: No limitation of physical activity. Ordinary physical activity does not cause undue fatigue, palpitation or shortness of breath. Class II: Slight limitation of physical activity. Comfortable at rest. Ordinary physical activity results in fatigue, palpitation, shortness of breath or chest pain. Class III: Marked limitation of physical activity. Comfortable at rest. Less than ordinary activity causes fatigue, palpitation, shortness of breath or chest pain. Class IV: Symptoms of heart failure at rest. Any physical activity causes further discomfort. |
2 Year
|
|
All-cause Mortality
Aikaikkuna: 3 year
|
Percentage of participants with all-cause mortality |
3 year
|
|
All Stroke
Aikaikkuna: 3 year
|
Incidence of stroke (disabling and non-disabling) |
3 year
|
|
Myocardial Infarction
Aikaikkuna: 3 Year
|
Incidence of MI |
3 Year
|
|
Incidence of Life-threatening Bleeding
Aikaikkuna: 3 Year
|
Incidence of life-threatening bleeding:
|
3 Year
|
|
Incidence of Prosthetic Valve Endocarditis
Aikaikkuna: 3 Year
|
Incidence of prosthetic valve endocarditis: Any one of the following:
|
3 Year
|
|
Incidence of Prosthetic Valve Thrombosis
Aikaikkuna: 3 Year
|
Incidence of Prosthetic valve thrombosis: Any thrombus attached to or near an implanted valve that occludes part of the blood flow path, interferes with valve function, or is sufficiently large to warrant treatment. *Valve-associated thrombus identified at autopsy in a patient whose cause of death was not valve related should not be reported as valve thrombosis. |
3 Year
|
|
Valve-related Dysfunction
Aikaikkuna: 3 Year
|
Incidence of valve-related dysfunction defined as moderate or severe prosthetic valve stenosis, or moderate or severe prosthetic regurgitation (per VARC II) |
3 Year
|
|
Incidence of Valve-related Dysfunction Requiring Repeat Procedure
Aikaikkuna: 3 Year
|
Incidence of Valve-related dysfunction requiring repeat procedure |
3 Year
|
|
Valve Hemodynamic Performance Metric - Mean Aortic Gradient
Aikaikkuna: 3 year
|
Mean aortic gradient |
3 year
|
|
Valve Hemodynamic Performance Metric - Effective Orifice Area
Aikaikkuna: 3 year
|
Effective orifice area |
3 year
|
|
Valve Hemodynamic Performance Metric - Degree of Aortic Regurgitation (Transvalvular, Paravalvular, Total)
Aikaikkuna: 3 year
|
Degree of aortic regurgitation (transvalvular, paravalvular, total) |
3 year
|
|
New York Heart Association (NYHA) Functional Classification
Aikaikkuna: 3 Year
|
New York Heart Association (NYHA) functional classification system is a tool that classifies patients with heart failure into one of four classes according to their degree of systems at rest and with activity. Below are the four classes and the associated patient symptoms (i.e., Class I has no limitations of physical activity vs. Class IV is most symptomatic and patient has symptoms of heart failure at rest). Class I: No limitation of physical activity. Ordinary physical activity does not cause undue fatigue, palpitation or shortness of breath. Class II: Slight limitation of physical activity. Comfortable at rest. Ordinary physical activity results in fatigue, palpitation, shortness of breath or chest pain. Class III: Marked limitation of physical activity. Comfortable at rest. Less than ordinary activity causes fatigue, palpitation, shortness of breath or chest pain. Class IV: Symptoms of heart failure at rest. Any physical activity causes further discomfort. |
3 Year
|
Yhteistyökumppanit ja tutkijat
Sponsori
Tutkijat
- Päätutkija: Jianan Wang, MD, Second Affiliated Hospital, Zhejiang University, School of Medicine
Opintojen ennätyspäivät
Opi tärkeimmät päivämäärät
Opiskelun aloitus (Todellinen)
Ensisijainen valmistuminen (Todellinen)
Opintojen valmistuminen (Arvioitu)
Opintoihin ilmoittautumispäivät
Ensimmäinen lähetetty
Ensimmäinen toimitettu, joka täytti QC-kriteerit
Ensimmäinen Lähetetty (Todellinen)
Tutkimustietojen päivitykset
Viimeisin päivitys julkaistu (Todellinen)
Viimeisin lähetetty päivitys, joka täytti QC-kriteerit
Viimeksi vahvistettu
Lisää tietoa
Tähän tutkimukseen liittyvät termit
Muut tutkimustunnusnumerot
- MDT18065EVR009
Lääke- ja laitetiedot, tutkimusasiakirjat
Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta
Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta
Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .